logo
  

AVITA Medical Launches RECELL System For Acute Thermal Burns In U.S.; Stock Up

Shares of AVITA Medical (AVH.AX, AVMXY) were gaining around 5 percent in Australian trading as the regenerative medicine company announced that it has commenced the U.S. national market launch of the RECELL Autologous Cell Harvesting Device or RECELL System for the treatment of acute thermal burns in patients 18 years and older.

The U.S. sales team of Regenerative Tissue Specialists and Clinical Training Specialists that joined AVITA Medical in November 2018 has been trained and fully deployed across the U.S. in support of the nationwide launch of the RECELL System.

In advance of the national launch, AVITA Medical has been actively fulfilling orders in response to strong market demand. AVITA said its new commercial team is now in active discussions with nearly half of the total number of burn centers across the U.S.

The company also announced the successful commercial results that have been achieved in advance of the national market launch. The company said 36 burns centers have begun the purchase authorization process with their hospital administration, 25 burn centers have been trained and certified in the use of the RECELL System, and 12 accounts have already placed orders and have received commercial shipments.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT